Ebglyss Dosing Change Shows How FDA Can Approve a New Schedule Through Modeling

FDA has approved a second maintenance schedule for Eli Lilly's Ebglyss (lebrikizumab-lbkz), allowing one 250 mg injection every eight weeks for adults and adolescents with moderate-to-severe atopic dermatitis, Lilly announced on June 9, 2026, as reported by Pharmaceutical Executive. The every-four-week maintenance dose remains approved, and both follow the same 16-week starting phase.

The decision is notable for how it was supported. The updated label says the effectiveness of the every-eight-week dose "was established using longitudinal exposure-response modeling," rather than through a randomized trial comparing the two schedules.

How a label changes after approval

Once a biologic is licensed, changes to its label go through supplements to the original application. Under the federal rule on changes to an approved biologics application, most labeling changes require a supplement, and "FDA approval must be obtained before distribution of the product with the labeling change." A narrower set of safety-driven changes, such as adding or strengthening a warning, can be made when the supplement is filed, under a category the rule calls "Changes Being Effected."

A new dosing schedule falls in the first group. FDA's approval letter, dated June 9, describes Lilly's filing as a "Prior Approval sBLA" that "provides for an additional maintenance dose option." The letter says FDA received it on Aug. 12, 2025, and Drugs@FDA lists it as supplement 6 to the Ebglyss application.

The letter also reminds Lilly of pediatric studies still owed under the Pediatric Research Equity Act, which applies to applications for new dosing regimens among other changes. It lists open requirements from the drug's September 2024 approval, including a trial in children from 6 months of age.

Where modeling fits

FDA's guidance on exposure-response relationships, issued in April 2003, describes how data linking drug levels in the body to clinical effects can be used to "interpolate previous clinical results to new dosages and dosing regimens not well studied in clinical trials." It gives switching from twice-a-day to once-a-day dosing as an example of a schedule change such data can sometimes support.

The guidance sets a limit. Exposure-response data "are not likely to be useful in lieu of clinical data in supporting new dosing schedules unless the relationship of the measured responses to relevant safety and efficacy outcomes is well understood."

For Ebglyss, the label reports that model predictions "were consistent" for the every-eight-week and every-four-week maintenance doses. It also shows lower drug levels at the longer interval: an average steady-state concentration of 26 mcg/mL every eight weeks, against 51 mcg/mL every four weeks.

Lilly also cited clinical data. According to Pharmaceutical Executive, the approval was supported by a 32-week, open-label extension of the Phase 3 ADjoin study in patients who had completed 100 weeks of treatment. The company reported no new safety signals and no discontinuations due to adverse events during the extension. The publication noted that the extension enrolled patients who had already responded to treatment, and that data from a randomized comparison of the two maintenance schedules are not available.